Reza Ali, MD
Nephrology · San Antonio, TXNPI 1669625448
Payments from drug & device makers
Across 278 payments — averaging $25.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- OPKO Pharmaceuticals, LLC$1K
- Amgen$824
- AstraZeneca$664
- Travere Therapeutics, Inc.$572
- Otsuka America Pharmaceutical, Inc.$390
- Bayer$307
- plus $3K from 24 others
What the payments were for
- Food & beverage$7,02699%
- Education$721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| OPKO Pharmaceuticals, LLC | 82 | $1,437 |
| Amgen(2 entities) | 35 | $824 |
| AstraZeneca(2 entities) | 22 | $664 |
| Travere Therapeutics, Inc. | 20 | $572 |
| Otsuka America Pharmaceutical, Inc. | 13 | $390 |
| Bayer | 12 | $307 |
| Mallinckrodt Hospital Products Inc. | 9 | $272 |
| GSK | 10 | $271 |
| Akebia Therapeutics Inc | 10 | $238 |
| Novo Nordisk | 6 | $234 |
| Aurinia Pharma U.S., Inc. | 6 | $233 |
| Corcept Therapeutics | 2 | $233 |
| Calliditas Therapeutics US Inc. | 4 | $173 |
| Lilly USA, LLC | 3 | $153 |
| Boehringer Ingelheim | 7 | $143 |
| Novartis | 6 | $137 |
| Vifor Pharma, Inc. | 6 | $131 |
| Mallinckrodt Enterprises LLC | 1 | $124 |
| Shield Therapeutics Inc | 6 | $90 |
| Ardelyx, Inc. | 4 | $89 |
| Baxter Healthcare | 1 | $86 |
| Nxstage Medical, Inc. | 2 | $69 |
| ANI Pharmaceuticals, Inc. | 3 | $62 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Cormedix Inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Arbor Pharmaceuticals, Inc. | 1 | $22 |
| AbbVie | 1 | $21 |
| Fresenius USA Marketing, Inc. | 1 | $18 |
| Amicus Therapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,098 in reported general payments places this provider in the 75th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RayaldeeCalcifediol | 82 | $140,906 |
| FarxigaDapagliflozin Propanediol | 162 | $134,261 |
| LupkynisVoclosporin | 12 | $116,753 |
| KerendiaFinerenone | 117 | $114,058 |
| VeltassaPatiromer Calcium Sorbitex | 57 | $77,731 |
| JardianceEmpagliflozin | 41 | $35,966 |
| LokelmaSodium Zirconium Cyclosilicate | 15 | $17,115 |
| OzempicSemaglutide | 13 | $15,545 |
| EntrestoSacubitril/Valsartan | 14 | $14,860 |
| MounjaroTirzepatide | 13 | $14,168 |
| ProcritEpoetin Alfa | 11 | $13,867 |
| Sevelamer Carbonate | 53 | $12,583 |
| Midodrine Hcl | 42 | $5,803 |
| Calcium Acetate | 14 | $2,715 |
| Nifedipine ErNifedipine | 53 | $1,122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $664 | $151,376177 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $1,437 | $140,90682 claims |
| Aurinia Pharma U.S., Inc.Lupkynis | $233 | $116,75312 claims |
| BayerKerendia | $307 | $114,058117 claims |
| Boehringer IngelheimJardiance | $143 | $35,96641 claims |
| Novo NordiskOzempic | $234 | $15,54513 claims |
| NovartisEntresto | $137 | $14,86014 claims |
| Lilly USA, LLCMounjaro | $153 | $14,16813 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $62 | $60223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,070 nephrology providers in Texas.
Other nephrology in San Antonio
- Pablo PergolaSan Antonio$14.2M
- Tahira AlvesSan Antonio$6.1M
- Carl DukesSan Antonio$5.9M
- Chinonye Ogbonnaya-OdorSan Antonio$4.6M
- Wesley CalhounSan Antonio$3.5M
- Shweta BansalSan Antonio$1.7M
- Robert SzewcSan Antonio$1.5M
- Rashid SharafSan Antonio$661K
- Varshasb BroumandSan Antonio$538K
- Luis VelezSan Antonio$505K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.